Skip to Content
COVID-19 Resources
Cancer Therapy Evaluation Program (CTEP)
Contact NExT
Show menu
Search this site
Last Updated: 07/29/21

List of Agents Available Under CTEP Collaborative Agreements for Clinical and Non-clinical Studies

Clinical Use

The clinical research supply of the CTEP agents, below, is largely for the National Clinical Trials Network (NCTN) and the Experimental Therapeutics Clinical Trials Network (ETCTN), however investigators from certain NCI-designated Cancer Centers not affiliated with these networks may submit a LOI. If approved, investigators may receive full ETCTN support for the clinical trial. Non-ETCTN NCI Cancer Centers will also be able to compete for administrative supplements to enroll patients on select ETCTN phase 2 trials through the NCI Early Drug Development Opportunity Program (EDDOP). Click here for more information about the EDDOP.

NOTE: It is very important for anyone thinking of developing an LOI to first communicate with the appropriate drug monitor, as listed on the table, before initiating work on the LOI.

Non-Clinical Use

The CTEP agents, below, are available to all requestors after NCI receives the industry supplier’s approval for the proposed research. For requests other than agents from AstraZeneca, please use the Non-clinical Request Form found at: Non-clinical Request. For AstraZeneca agents please use the AZ Non-clinical Request Form. For any other questions, please email NCICTEPRequests@mail.nih.gov.

OTHER AGENTS: If the agent you are looking for is not on this list please also check the NCI Formulary.

NOTE: this list can be sorted by clicking on any of the header names. For an Excel Spreadsheet of these agents please click here.

CAUTION: The table is not a 'live' document. It is updated about 4 times per year, so should never be assumed to contain the most recent changes. Please feel free to contact the appropriate drug monitor, as listed on the table to confirm accuracy.

Agents Available Under CTEP Collaborative Agreements for Clinical and Non-clinical Studies as of 7/28/2021

Agent Name Alternate Name Pharmaceutical Collaborator NSC Number Drug Monitor Mechanism of Action Targets Classes
abemaciclib LY2835219 Eli Lilly 783671 Piekarz CDK4/6 inhibitor CDK4/6 Small Molecule
AMG510   Amgen 825510 Wright Inhibits G12C-mutated KRAS mutated KRAS protein Small Molecule
anetumab ravtansine* BAY 94-9343 Bayer 791065 Moscow Anti cell surface glycoprotein mesothelin conjugated to maytansinoid DM4 with potential antineoplastic activity mesothelin Antibody-Drug Conjugate; Monoclonal Antibody
APG-1252*** Pelcitoclax Ascentage 831685 Gore Inhibits B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma — extra-large (Bcl-xL) anti-apoptotic Bcl-2 family proteins, including Bcl-2, Bcl-xL, Bcl-w, and Mcl-1 Small Molecule
ASTX727 Fixed-Dose Combination of cedazuridine and decitabine Astex Pharmaceuticals 820631 Piekarz DNA methyltransferase (DNMT) inhibitor DNA methyltransferase Small Molecule
Atezolizumab MPDL3280A Genentech 783608 Sharon Targets PD-L1 expressed on tumor and infiltrating immune cells, preventing binding to PD-1 and B7.1 programmed cell death ligand 1 (PD-L1) Monoclonal Antibody
AZD5363 Capivasertib AstraZeneca 782347 Sandlund Inhibits all AKT isoforms AKT Small Molecule
AZD6738   AstraZeneca 802785 Gore Inhibits Ataxia Telangiectasia and Rad3 related (ATR) serine/threonine protein kinase ATR Small Molecule
BAY1895344   Bayer 810486 Gore Inhibitor of ataxia telangiectasia mutated and Rad3-related (ATR) kinase ATR Small Molecule
Belinostat PXD 101 Acrotech Biopharma 726630 Piekarz Histone deacetylase inhibition Histone deacetylase Hydroxamic acid
bevacizumab rhuMAb VEGF Genentech 704865 Pickett Binds VEGF to prevent its binding to VEGFR; angiogenesis inhibition VEGF Monoclonal Antibody(Humanized)
blinatumomab AMG-103, MT-103 Amgen 765986 Sharon bispecific (BiTE specific) antibody targeting CD19 CD19 Monoclonal Antibody
bortezomib PS-341 Takeda/Millennium 681239 Wright 26S proteosome inhibition (stabilizes p53, p27; inhibits NF-kB activation; alters cyclin-mediated regulation of cell cycle progression) Proteosome Inhibitor(Proteosome - Complex) Small Molecule
brentuximab vedotin SGN-35 Seattle Genetics 749710 Pickett An antibody drug conjugate targeting CD30 and using an MMAE payload CD30 Antibody-Drug Conjugate
CA-4948 Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4) Inhibitor Curis, Inc. 824184 Pickett Inhibits IL-R signaling Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4) Small Molecule
cabozantinib XL-184 Exelixis 761968 Wright c-Met; VEGFR2 inhibition c-Met; VEGFR2 Small Molecule
cediranib AZD2171 AstraZeneca 732208 Ivy Angiogenesis inhibitor, VEGFR1, VEGFR2, VEGFR3, PDGFR alpha and beta, FGFR1 VEGFRs, PDGFRs, FGFR1 Small Molecule
Cobimetinib RO5514041, GDC0973 Genentech 781257 Wright Inhibits MAPK signaling pathway MEK1 and MEK2 Small Molecule
copanlisib BAY-80-6946 Bayer 784727 Sandlund Phosphoinositide 3-kinase (PI3K) inhibitor pan-PI3K, particularly PI3K-alpha, delta Small Molecule
dabrafenib mesylate* GSK2118436B Novartis 763760 Chen BRAF inhibition of BRAFV600 mutations BRAF Small Molecule
darolutamide BAY-1841788 Bayer 815949 Wright A novel nonsteroidal androgen receptor (AR) antagonist androgen receptor (AR) Small Molecule
dinutuximab Ch14.18 United Therapeutics 623408 Moscow Antibody against GD2 GD2 Monoclonal Antibody (chimeric)
durvalumab MEDI4736 AstraZeneca/Medimune 778709 Chen Check point inhibitor. Antibody against programmed cell death ligand 1 (PD-L1) PD-L1 Monoclonal Antibody
erdafitinib JNJ-42756493 Janssen Research and Development 781558 Piekarz Inhibits signaling of Fibroblast Growth Factor Receptor (FGFR) Subtypes 1-4 FGFR1-4 Small Molecule
eribulin (halichondrin B analog) E7389 Eisai 707389 Piekarz Antitubulin agent Structural Component(Tubulin - Protein) Small Molecule
ganitumab* AMG-479 ImmunityBio 750008 Chen Insulin-like Growth Factor-1 Receptor (IGF-1R) antibody IGF-1R Small Molecule
GMI-1271 uproleselan GlycoMimetics 801708 Gore A specific E-selectin inhibitor (antagonist), putatively disrupting leukemia cell survival pathways and enhancing chemotherapy response E-selectin Antineoplastic, Antithrombotic, Glycolipid, Small Molecule
guadecitabine* SGI-110 Astex 780463 Piekarz Inhibits DNA synthesis and DNA methylation. The latter mechanism may lead to re-expression of selected genes DNMT Small Molecule
ibrutinib PCI-32765 Pharmacylics 748645 Ivy Bruton’s Tyrosine Kinase (BTK) inhibitor BTK Small Molecule
idUrd Prodrug IPdR NCI 726188 Piekarz Prodrug of iododeoxyuridine DNA polymerase Small Molecule
interleukin-12 IL-12 NCI 672423 Streicher Made mainly by dendritic cells and macrophages. Causes other immune cells to make cytokines and increases the growth of T lymphocytes. It may also block the growth of new blood vessels. Binds to the IL-12 receptor found on activated T cells Upon binding, IL-12R-β2 provides binding sites for Tyk2 and Jak2, activating STAT4 Pleiotropic Cytokine
interleukin-15 IL-15 NCI 745101 Streicher Cytokine that regulates T and natural killer cell activation and proliferation. Shares many biological activities with interleukin 2 Activates JAK kinases, and phosphorylation/activation of transcription activators STAT3, STAT5 and STAT6. Cytokine
ipatasertib GDC-0068 Genentech 781451 Sandlund an ATP-competitive AKT inhibitor, blocks the phosphoinositide 3-kinase (PI3K)/AKT pathway all three isoforms of AKT small molecule
ipilimumab (transfectoma-derived) MDX-010 Bristol-Myers Squibb 732442 Streicher Inhibits the B7/CTLA-4 interaction and down regulates T-cell response CTLA-4 - Antigen Monoclonal Antibody
ixazomib MLN9708 Takeda/Millennium 767907 Wright An orally bioavailable second generation proteasome inhibitor (PI) with antineoplastic activity Proteasome Small Molecule
lenalidomide CC-5013 Celgene 703813 Streicher Antiangiogenic; immunomodulatory (stimulates T-cell proliferation, increases interleukin-2 (IL-2), IL-10, interferon-gamma (IFN-g) production; inhibits tumor necrosis factor-alpha (TNF-alpha), IL-1beta, IL-12 and IL-6) Angiogenesis (VEGF - Unknown), Immune System (T-cell, IL-2, IL-6, IL-10, IL-12, IL-1beta, TNF-alpha, IFN-gamma - Unknown) Small Molecule
Lutetium Lu177 Dotatate Novartis   Wright Radiopharmaceutical that binds to somatostatin receptor, is internalized and accumulates in lysosomes. Somatostatin receptor Radiopharmaceutical
M3814 MSC2490484A EMD Serono (Merck KGaA) 802447 Gore DNA-PK inhibition, delay DNA repair of the DSB pathway in solid tumors and hematologic malignancies DNA-dependent protein kinase (DNA-PK) Small Molecule
M6620 VX-970 EMD Serono (Merck KGaA) 780162 Gore Inhibitor of ataxia telangiectasia mutated and Rad3-related (ATR) kinase ATR Small Molecule
MEDI-570   AstraZeneca 783606 Moscow Antagonistic Antibody Against Inducible Co-stimulator (ICOS) ICOS Monoclonal Antibody
methoxyamine hydrochloride TRC-102 Tracon 3801 Gore Small molecule inhibitor of the DNA Base Excision Repair (BER) pathway BER Small Molecule
mogamulizumab KW-0761 Kyowa Kirin 791064 Sharon Defucosylated humanized IgG1 mAb against C-C chemokine receptor 4 (CCR4) C-C chemokine receptor 4 Monoclonal Antibody
nivolumab BMS-936558 Bristol-Myers Squibb 748726 Streicher Humanized IgG4 mAb against programmed death 1 receptor (PD-1) PD-1 Antibody
olaparib AZD2281 AstraZeneca 747856 Ivy Polyadenosine 5’diphosphoribose[poly (ADP ribose)] Polymerase (PARP) inhibitor, PARylation inhibitor and PARP trapper, Class II, moderate trapper. Binding prevents PARP-mediated DNA repair of single strand DNA breaks via base-excision repair PARP Small Molecule
osimertinib AZD9291 AstraZeneca 781254 Moscow 3rd generation epidermal growth factor receptor mutation (mEGFR) inhibitor mEGFR and the dominant acquired T790M resistance mutation Small Molecule
pembrolizumab MK-3475 Merck 776864 Sharon Humanized IgG4 mAb against programmed death 1 receptor (PD-1) PD-1 Antibody
pevonedistat TAK-924, MLN4924 Takeda/Millennium 793435 Wright A small molecule inhibitor of Nedd8 activating enzyme (NAE) with potential antineoplastic activity Nedd8 activating enzyme Small Molecule
pomalidomide CC-4047 Celgene/BMS 767909 Streicher Angiogenesis inhibitor, vascular endothelial growth factor (VEGF) inhibition Angiogenesis(VEGF - Protein), Angiogenesis(TNF - Protein) Small Molecule
radium223 Radium223 Bayer 793433 Wright alpha particle-emitting radionuclides   Radiopharmaceutical
relatlimab** BMS-986016 Bristol-Myers Squibb   Streicher inhibitor of the LAG-3 checkpoint receptor LAG-3 Monoclonal Antibody
rociletinib* CO-1686 Clovis Oncology 783605 Moscow 3rd generation mEGFR inhibition mEGFR and the dominant acquired T790M resistance mutation Small Molecule
savolitinib AZD6094 AstraZeneca 785348 Wright specific, small molecule inhibitor of the MET receptor kinase cMet Small Molecule
selinexor XPOVIO Karyopharm Therapeutics 781780 Gore Selective Inhibitor of Nuclear Export nuclear export protein, XPO1 Small Molecule
selumetinib* AZD6244 AstraZeneca 748727 Wright MAPK/ERK Kinase (MEK) inhibition MEK enzyme Small Molecule
sorafenib tosylate BAY 43-9006, BAY 54-9085 Bayer 724772 Wright Raf kinase inhibitor, receptor tyrosine kinase (RTK) inhibitor (VEGFR-2, Flt3, cKIT), PDGFR inhibitor, Ret inhibitor, angiogenesis inhibition Signal Transduction(Raf kinase, VEGFR2, PDGFR, c-kit - Protein) Small Molecule(Bi-aryl urea)
sunitinib malate SU011248, L-malate Pfizer 736511 Gore Angionenesis inhibitor: PDGFR alpha/beta,VEGFR 1,2,3,KIT, RET, CSF-1R,FLT3 VEGF2, c-KIT, Flt-3, and PDGFR beta Small Molecule
talazoparib BMN 673 (MDV 38000) Pfizer 771561 Ivy Polyadenosine 5’diphosphoribose[poly (ADP ribose)] Polymerase (PARP) inhibitor, PARylation inhibitor and PARP trapper, Class II, strong trapper. Binding prevents PARP-mediated DNA repair of single strand DNA breaks via base-excision repair PARP 1 and 2 inhibitor Small Molecule
tazemetostat EPZ-6438 (clinical)
EPZ011989 (pre-clinical)
Epizyme 791066
795999
Piekarz Small molecule inhibitor of histone methyltransferase EZH2 EZH2 Small Molecule
telaglenastat CB-839 Calithera 795998 Piekarz inhibitor of human glutaminase glutaminase Small Molecule
thorium227 Thorium227 Bayer 840487 Wright alpha particle-emitting radionuclides   Radiopharmaceutical
Tin-117m-DTPA   Serene   Wright Radiopharmaceutical that selectively accumulates in bone metastases   Radiopharmaceutical
trametinib* GSK112021 Novartis 763093 Chen Potent and highly selective inhibitor of MEK1/2 activation and kinase activity MEK enzyme Small Molecule
trastuzumab deruxtecan DS-8201a Daiichi Sankyo 807708 Pickett HER2-targeted antibody-drug conjugate - inhibits topoisomerase I which leads to apoptosis of the target cells Human Epidermal Growth Factor Receptor 2 (HER2) Monoclonal Antibody-drug conjugate
TRC-105   Tracon 754227 Gore monoclonal antibody for CD105 CD105 Monclonal Antibody
triapine   Nanopharmaceutics 663249 Ivy Ribonucleotide reductase (RR) inhibitor inhibits the metal binding subunit (M2) of RR, which is essential for DNA synthesis and repair. DNA Synthesis(RR M2 subunit - Enzyme) Small Molecule
varlilumab CDX-1127 Celldex 778372 Sharon fully human monoclonal antibody that targets CD27 CD27 and activates tumor specific T cells Monocloncal Antibody
veliparib ABT-888 Abbvie 737664 Ivy Polyadenosine 5’diphosphoribose[poly (ADP ribose)] Polymerase (PARP) inhibitor, PARylation inhibitor and PARP trapper, Class I, weak trapper. Binding prevents PARP-mediated DNA repair of single strand DNA breaks via base-excision repair PARP-1 and PARP-2 inhibitor Small Molecule
venetoclax ABT-199 Abbvie/Genentech 766270 Gore Bcl-2-selective inhibitor that disrupts Bcl-2 signaling in cells and rapidly induces multiple hallmarks of apoptotic cell death in Bcl-2-dependent tumor cells Bcl-2 and with lower affinity to Bcl-XL and Bcl-w Small Molecule
VXc-984* M9831 EMD Serono (Merck KGaA) 789705 Gore DNA-PK inhibition DNA-dependent protein kinase (DNA-PK) Small Molecule
ZEN-3694 ZEN003694 Zenith Epigenetics Ltd. 824453 Piekarz epigenetically regulates gene expression through BET inhibition, targeting BET proteins leads to inhibition of tumor growth in multiple cancer types, through cell cycle arrest and induction of senescence and apoptosis.
Bromodomain and Extra-Terminal motif (BET) inhibitor Small Molecule
z-endoxifen HCI   NCI 750393 Streicher Endoxifen, a cytochrome P450 mediated tamoxifen metabolite, is an anti-estrogen Targets estrogen receptor-alpha Small Molecule
ziv-aflibercept VEGF-Trap Sanofi Aventis 724770 Ivy Chimeric IgG-VEGFR-1+VEGFR-2 molecule binds to VEGF to prevent its binding to VEGFR-1(Flt-1) and VEGFR-2 (KDR/Flk-1) receptors; angiogenesis inhibition VEGF Protein

* - Non-clinical requests only  ** - Only available in combination with nivolumab  *** - Only available for solid tumor indications